Auxilium Pharmaceuticals and Actelion Pharmaceuticals have entered into a long-term partnership for the development, supply and commercialization of Xiaflex, a novel, first-in-class biologic for the potential treatment of Dupuytren’s contracture and Peyronie’s disease. Upon approval, Actelion will have exclusive rights to commercialize Xiaflex in Canada, Australia, Brazil and Mexico, and will be responsible for regulatory and commercialization activities in these countries. Xiaflex is approved ...